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Abstract
Aims: A number of intervention studies have shown that therapy with angiotensin receptor
blockers, such as irbesartan, can improve metabolic parameters and reduce the incidence of
diabetes mellitus. It is unknown whether this observation also holds true in routine clinical settings.
Methods: We evaluated the effect of irbesartan (150 mg or 300 mg/d) together with or without
hydrochlorothiazide (12.5 mg/d) in 3259 German patients. A total of 750 primary care physicians
evaluated up to 5 subsequent patients with metabolic syndrome (58.9% diabetic), in whom
irbesartan therapy was newly initiated (87%) or continued (13%).
Results: Six months of irbesartan therapy decreased systolic blood pressure by 14% (157.4 ± 14.7
vs. 135.0 ± 10.7 mmHg) and diastolic blood pressure by 13% (92.9 ± 9.2 vs. 80.8 ± 6.8 mmHg). This
was associated with a decrease in body weight (-2.3%), fasting glucose (-9.5%), HbA1c (-4.6%), LDL-
cholesterol (-11%), triglycerides (-16%) and gamma-GT (-12%) and an increase in HDL-cholesterol
(+5%). These changes were somewhat more pronounced in male than in female patients and in
obese than in lean patients. Changes in glucose concentration and HbA1c were much more
prominent in diabetic patients.
Conclusion: Irbesartan therapy improves metabolic parameters in routine clinical settings. Thus,
our study confirms previously published results from large intervention trials and extends the
findings to routine clinical practice.
Introduction
The metabolic syndrome which describes the concomi-
tant presence of visceral obesity, insulin resistance or glu-
cose intolerance, atherogenic dyslipidemia and
hypertension is highly prevalent (approximately 25%) in
Germany. The risk of developing diabetes mellitus type 2
for subjects with the metabolic syndrome is increased five-
to nine-fold [1,2]. In addition, all components of the met-
abolic syndrome are common cardiovascular risk factors.
Therefore patients with this syndrome have a two-four
fold increase in risk for cardiovascular disease and death
[3].
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Large clinical trials evaluated the effect of angiotensin
receptor blockers (ARB) on cardiovascular end points,
generally showing very positive results. Therefore ARB and
ACE-Inhibitors are now considered first line therapy in
hypertensive patients with the metabolic syndrome [4,5].
An analysis of co-morbidity showed that such therapy
also substantially lowers the risk for type 2 diabetes com-
pared with other antihypertensive drugs and compared
with placebo [6-8]. Furthermore, it lowers cardiovascular
mortality independent of its antihypertensive effects. The
reduced incidence of diabetes in ARB trials was associated
with lowering of blood pressure, but independent of other
predictors for diabetes development. Furthermore, an
anti-inflammatory effect by treatment was observed, as
well as an influence on the metabolism of free fatty acids,
which could mediate the observed reduction in type 2 dia-
betes incidence. On the other hand, a recently published
intervention trial which specifically aimed at reducing the
incidence of type 2 diabetes with the ACE inhibitor rami-
pril failed to show a significant reduction in new onset
diabetes, although average glucose concentration was
decreased compared to placebo [9].
Thus, a large body of data indicates that interfering with
the angiotensin system has positive effects on metabolic
parameters. However, it is unknown whether these posi-
tive effects can also be observed in daily routine clinical
practice, although recently published data from a post
authorization trial indicate that this may be the case [10].
We therefore conducted an observational study in a large
group of German hypertensive patients. The aim of this
study was to evaluate the effect of irbesartan with and
without hydrochlorothiazide on parameters of glucose
metabolism, lipid metabolism, renal function, and blood
pressure.
Methods
A total of 3259 patients participated in this prospective, 6-
month, open-label, observational, post-authorization sur-
vey. The patients were recruited from 649 general practi-
tioners throughout Germany, who included up to 5
subsequent patients who fulfilled the inclusion criteria
specified below and who at the time of the index visit were
either already on irbesartan therapy or in whom irbe-
sartan therapy was started at that time point. All subjects
had elevated blood pressure (>130/85 mmHg or antihy-
pertensive therapy). In addition, at least two of the follow-
ing criteria were present: abdominal obesity (waist-
circumference >102 cm (male) or >88 cm (female)), ele-
vated triglycerides (>150 mg/dl), decreased HDL-choles-
terol (male <40 mg/dl, female <50 mg/dl), elevated
fasting glucose (>110 mg/dl). The characteristics of the
subjects are shown in Table 1.
Each subject was evaluated three times: At baseline (index
visit), after three months and after six months. Patients
were evaluated using a standardized form with which data
on duration of hypertension, duration of metabolic syn-
drome, nicotine and alcohol consumption, blood pres-
sure, pulse, weight, height, waist circumference,
medications, lab-values (HbA1c, fasting glucose, fasting
LDL-cholesterol, fasting HDL-cholesterol, fasting triglyc-
erides, creatinine, hs-CRP, gamma-GT) were collected.
Mean and standard deviation as well as median and range
were used to describe the population. t-tests were used to
evaluate intergender differences, differences between dia-
betic and non-diabetic patients, and differences between
different doses. Non-parametric tests were used for statis-
tical evaluation were appropriate. SAS, version 9.1 was
used for statistical analysis. The analysis was performed by
GKM – Gesellschaft fuer Therapieforschung, Munich, Ger-
many.
Table 1: Parameters of study participants at baseline
Parameter All Men Women
n 3259 64.1% 35.9%
Age [years] 61.5 ± 10.5 60.2 ± 10.0 63.7 ± 10.8*
BMI [kg/m2] 30.9 ± 4.8 30.8 ± 4.4 31.0 ± 5.3
Waist-circumference [cm] 106.4 ± 13.6 110.2 ± 11.9 99.2 ± 13.7*
RRsystolic [mmHg] 157.4 ± 14.7 157.5 ± 14.5 157.2 ± 15.1
RRdiastolic [mmHg] 92.9 ± 9 93.3 ± 9.1 92.2 ± 9.5*
Fasting plasma glucose (FPG) [mg/
dl]
126.4 ± 37.1 126.6 ± 37.3 126.0 ± 36.7
LDL-cholesterol [mg/dl] 144.9 ± 38.2 144.8 ± 38.5 145.2 ± 37.5
HDL-cholesterol [mg/dl] 48.4 ± 31.8 46.2 ± 30.9 52.6 ± 33.2*
Triglycerides [mg/dl] 217.4 ± 114.9 221.1 ± 127.7 209.9 ± 85.8*
Hs-CRP [mg/l] 4.81 ± 7.95 5.13 ± 8.38 3.75 ± 6.26
Gamma-GT [U/l] 52.9 ± 47.1 58.7 ± 50.6 40.6 ± 34.8*
BMI = body-mass index; * p < 0.01 for intergender differences;Cardiovascular Diabetology 2007, 6:36 http://www.cardiab.com/content/6/1/36
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Results
In this cohort of German hypertensive patients 49.1% did
not take any antihypertensive medications at the index
visit, while 50.9% were taking at least one antihyperten-
sive drug. At baseline 423 patients (13.2%) were taking
irbesartan, while in all others irbesartan therapy was initi-
ated at the index visit. Furthermore, the patients were also
taking a significant number of other medications (Table
2). This concomitant medication did not change during
the observation period.
In this study 594 patients (18.8%) were treated with irbe-
sartan 150 mg/d, 665 patients (21%) with irbesartan 300
mg/d, 754 patients (23.8%) with 150 mg irbesartan and
12.5 mg hydrochlorothiazide and the rest (36.4%) with
irbesartan 300 mg/d and 12.5 mg hydrochlorothiazide.
During the observation period the number of patients
treated with irbesartan 150 mg/d decreased slightly (from
42.6% to 37.0%) while those groups taking 300 mg/d
increased (from 57.4% to 63%).
Within the observation period (6 months) systolic blood
pressure decreased from 157.4 ± 14.7 mmHg to 135.0 ±
10.9 mmHg (-22.3%). Diastolic blood pressure decreased
from 92.9 ± 9.2 mmHg to 80.8 ± 6.8 mmHg (-12.1%).
Thus, the rate of patients with systolic blood pressure
<130 mmHg increased from 1.6% to 20.4%. While the
rate of patients with systolic blood pressure >180 mmHg
decreased from 9.4 to 0.4%. Similarly, diastolic blood
pressure was <85 mmHg in 15.7% at the index visit and
67% after 6 months of therapy. The rate of patients who
had blood pressure <140/90 mmHg increased from 4.9 to
59.2%.
During the observation period the body weight decreased
from 91.4 ± 15 kg to 89.3 ± 14.6 kg (-2.2%). This decrease
was somewhat more pronounced in men (-2.5%) than in
women (-1.4%). Similarly waist circumference decreased
from 106.4 to 104.3 cm (all: -2.1%; men -2.6%; women -
1.3%).
The effect on metabolic parameters is shown in Table 3.
Overall we observed a reduction in HbA1c, fasting glu-
cose, LDL-cholesterol, fasting triglycerides, Hs-CRP,
Gamma-GT and an increase in HDL-cholesterol. Gener-
ally, these changes in metabolic parameters were more
pronounced in patients receiving 300 mg irbesartan/d
compared to those receiving 150 mg/d (Table 4). The
effect on metabolic parameters was independent of the
medication that the patients were receiving at the index
visit.
All metabolic changes were more pronounced in men
than in women, in younger (<62 years) than in older (≥62
years), in more obese (BMI ≥30 kg/m2) than in leaner
patients. HbA1c and fasting glucose reduction was signif-
icant in diabetic and non-diabetic patients, but was much
more pronounced in those with diabetes. All other param-
eters decreased in diabetic and non-diabetic patients,
however, improvement was overall more pronounced in
patients with diabetes (Figure 1). Within the group of dia-
betic patients we did not observe an influence of the
underlying anti-diabetic treatment on the metabolic effi-
cacy of irbesartan (data not shown). In a multivariate
analysis it was shown that changes in HbA1c and glucose
were mostly related to BMI while changes in LDL-choles-
terol and triglycerides were related to age. Furthermore,
triglycerides, HDL-cholesterol and HbA1c were correlated
with sex.
All metabolic changes were significantly correlated with
the changes in blood pressure, although the correlation
coefficients were low (Table 5). Changes in systolic blood
pressure correlated best with changes in HbA1c, while
changes in diastolic blood pressure correlated best with
changes in LDL-cholesterol and triglycerides.
Discussion
In our study performed in routine clinical practice six
months of irbesartan therapy resulted in a considerable
improvement in a number of metabolic parameters. We
observed a significant reduction in HbA1c, fasting glu-
cose, LDL-cholesterol, fasting triglycerides, gamma-GT
and hs-CRP.
Table 2: Accompanying diagnosis and medication at baseline
Parameter n %*
Diabetes mellitus 1921 58.9
Hepatic steatosis 1258 38.6
Coronary artery disease 773 23.7
Benign prostatic hyperplasia 365 11.2
Nephropathy 315 9.7
Cardiac failure 306 9.4
Myocardial infarction 272 8.3
Cerebrovascular event 176 5.4
Active smoker 680 20.9
Former smoker 1012 31.1
Statins 1471 45.1
Orale antidiabetic drugs 1298 39.8
Betablockers 1088 33.4
Platelet Inhibitors 957 29.4
Calciumantagonists 735 22.6
Diuretics 637 19.5
Insulin 420 12.9
ACE-Inhibitors 337 10.3
Fibrates 200 6.1
Medications reported in less than 3% are not indicated in the table; * 
sum >100% because some patients were taking more than 1 
medication.Cardiovascular Diabetology 2007, 6:36 http://www.cardiab.com/content/6/1/36
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These changes in metabolic parameters were somewhat
dose dependent, thus more pronounced in patients
receiving 300 mg irbesartan compared to those receiving
150 mg/d. Concomitant therapy with thiazide did not
affect these changes. Overall the metabolic changes were
more pronounced in men and more pronounced in over-
weight and obese subjects. The observed changes were
strongly related to changes in blood pressure.
Our observations are consistent with previous interven-
tion trials. Large clinical trials showed that ARB therapy
substantially lowers the risk for type 2 diabetes compared
to other antihypertensive therapies or placebo [6-8]. Fur-
thermore, in a recently published subanalysis of the Treat
to Target post authorization survey in 14200 patients very
similar results were observed. There was a significant
improvement in blood pressure and metabolic risk factors
as a result of Irbesartan treatment. Similar to our study
there was no evidence of a difference between mono-
therapy and combination therapy with hydrochlorothi-
azide with regard to the cardiovascular risk profile [10].
While Kintscher and colleagues [10] investigated hyper-
tensive patients with and without metabolic syndrome,
we studies only metabolic syndrome patients including a
large number of diabetic patients. Despite this difference
the over-all results are very similar indicating that a broad
range of patients benefit from such therapy with respect to
metabolic parameters. However, it should also be noted
that in both studies patients with supposedly more severe
insulin resistance benefited the most.
In addition, a number of small clinical trials have evalu-
ated the effect of ARB therapy on individual components
of the metabolic syndrome particularly on glucose metab-
olism [11-13]. It is currently unclear whether individual
ARB differ in their potential to improve metabolic param-
eters, although telmisartan and irbesartan seem to be par-
ticularly powerful in this respect [14,15].
Several mechanisms could link ARB therapy with an
improvement in metabolic parameters. ARB may improve
insulin sensitivity by affecting inflammatory processes
and altering free fatty acid concentration and/or metabo-
lism [16]. Furthermore, ARB could directly stimulate
PPAR-gamma [17-19].
Our study extends the known findings to the "every day"
routine clinical practice. The magnitude of improvement
Table 3: Effect of irbesartan on metabolic parameters in patients with metabolic syndrome
Parameter Baseline On Therapy Changea Changeb p-valuec
Body weight [kg] 91.4 ± 15.0 89.3 ± 14.6 -2.1 ± 7.9 -2.3 < 0.0001
Waist-circumference [cm] 106.4 ± 13.6 104.3 ± 13.2 -2.1 ± 7.9 -2.0 < 0.0001
RRsystolic [mmHg] 157.4 ± 14.7 135.0 ± 10.7 -22.3 ± 15.3 -14.2 < 0.0001
RRdiastolic [mmHg] 92.9 ± 9.2 80.8 ± 6.8 -12.1 ± 9.9 -13.0 < 0.0001
Glucose [mg/dl] 126.4 ± 37.1 114.5 ± 29.4 -12.0 ± 30.7 -9.5 < 0.0001
HbA1c [%] 6.74 ± 1.14 6.43 ± 0.91 -0.31 ± 0.75 -4.6 < 0.0001
LDL-cholesterol [mg/dl] 144.9 ± 38.2 129.1 ± 31.8 -15.8 ± 30.5 -10.9 < 0.0001
HDL-cholesterol [mg/dl] 48.4 ± 31.8 51.0 ± 15.9 2.6 ± 31.8 5.4 < 0.0001
Triglycerides [mg/dl] 217.4 ± 114.9 182.5 ± 76.7 -34.9 ± 100.9 -16.1 < 0.0001
Gamma-GT [U/l] 52.9 ± 47.1 46.8 ± 38.9 -6.1 ± 30.2 -11.5 < 0.0001
Hs-CRP [mg/l] 4.81 ± 7.95 4.01 ± 6.74 -0.79 ± 6.72 -16.4 < 0.0001
a absolute change; b relative change (%); c p-values for absolute change
Table 4: Dose dependent effects of irbesartan on metabolic parameters in patients with metabolic syndrome
Parameter 150 mg/da 300 mg/da p-valueb 150 mg/d + HCTa 300 mg/d + HCTa p-valuec
Glucose [mg/dl] -9.1 ± 30.5 -12.3 ± 34.7 0.092 -7.8 ± 23.9 -14.3 ± 30.7 < 0.0001
HbA1c [%] -0.24 ± 0.8 -0.30 ± 0.8 0.223 -0.26 ± 0.6 -0.34 ± 0.7 0.035
LDL-cholesterol [mg/dl] -11.2 ± 26.92 -16.6 ± 30.4 0.004 -12.4 ± 26.4 -17.3 ± 33.3 0.001
HDL-cholesterol [mg/dl] 1 ± 37.4 2.8 ± 25.6 0.393 2.1 ± 22.6 4.1 ± 33.6 0.156
Triglycerides [mg/dl] -27.4 ± 75.8 -31.0 ± 73.6 0.440 -30.9 ± 68.9 -40.3 ± 133.9 0.060
Gamma-GT [U/l] -4.7 ± 37.2 -7.3 ± 24.2 0.257 -4.2 ± 21.7 -6.4 ± 32.4 0.142
Hs-CRP [mg/l] -0.42 ± 2.9 -0.80 ± 10.5 0.704 -0.47 ± 1.4 -1.25 ± 7.2 0.111
a absolute change; b relates to difference between irbesartan 150 mg/d and irbesartan 300 mg/d; c relates to difference between irbesartan 150 mg/d 
with HCT (12.5 mg/d) and irbesartan 300 mg/d with HCT (12.5 mg/d).Cardiovascular Diabetology 2007, 6:36 http://www.cardiab.com/content/6/1/36
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is similar to that seen in placebo controlled intervention
trials. It is however important to confirm these studies in
more typical settings, because patients included in pla-
cebo controlled intervention trials are usually highly
selected which could bias results. On the other hand our
open-label, observational design also results in considera-
ble limitations. Thus, it should be noted, that all sub-
groups including those that were already on ARB therapy
or ACE inhibitor therapy at the beginning benefited with
respect to their metabolic parameters. This indicates that
part of the improvement in metabolic parameters is
related to the fact that the patients were included in this
observational study (study-in effect). Notably, we also
observed a small but significant decrease in body weight,
which also indicates that some of the beneficial effects
observed during the study are related to the study-in
effect. On the other hand, as outlined above, irbesartan
stimulates PPAR-gamma dependent pathways and thus
results in an altered flux of free fatty acids, which may
affect nutritional behavior and caloric intake. Further-
more, metabolic improvement was related to blood pres-
sure reduction. It therefore cannot be decided whether the
improvement in metabolic parameters is specific for irbe-
sartan (or ARB therapy) or the result of blood pressure
reduction. However, a number of large intervention trials
have shown that the effect of ARB therapy on metabolic
parameters reaches beyond blood pressure reduction.
Conclusion
The present study indicates that hypertensive patients
with metabolic syndrome with and without diabetes ben-
efit from irbesartan therapy not only with respect to blood
pressure reduction but also with respect to a significant
improvement of metabolic parameters such as glucose,
lipids and liver values.
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